N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors-Reference-Cited by-同舟云学术

N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors

Published:2005-05-18 Issue:11 Volume:30 Page:1986-1995
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Li Zhu,Huang Mei,Ichikawa Junji,Dai Jin,Meltzer Herbert Y

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/1300768.pdf

Reference81 articles.

1. Adler G, Grieshaber S, Faude V, Thebaldi B, Dressing H (2002). Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance. Pharmacopsychiatry 35: 190–194.

2. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM et al (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6: 51–58.

3. Aravagiri M, Marder SR (2001). Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J Pharm Biomed Anal 26: 301–311.

4. Aura J, Sirvio J, Riekkinen Jr P (1997). Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test. Eur J Pharmacol 333: 129–134.

5. Baghdoyan HA, Lydic R, Fleegal MA (1998). M2 muscarinic autoreceptors modulate acetylcholine release in the medial pontine reticular formation. J Pharmacol Exp Ther 286: 1446–1452.

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of Population Pharmacokinetic Models for Clozapine Dosage Prediction;Therapeutic Drug Monitoring;2024-02-27

2. Effect of anticholinergic burden on brain activity during Working Memory and real-world functioning in patients with schizophrenia;Schizophrenia Research;2023-10

3. Novel Compounds in the Treatment of Schizophrenia—A Selective Review;Brain Sciences;2023-08-11

4. Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives;Frontiers in Pharmacology;2022-10-12

5. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia;American Journal of Psychiatry;2022-09-01